BACKGROUND Identification of novel biomarkers is needed to improve the diagnosis and prognosis of heart failure
Previously, on the basis of analysis of urine samples from a limited number of patients, Kang et al. (6) showed that concentrations of 1-methylnicotinamide, 2-oxoglutarate, and pyruvate were lower in patients with ischemic HF, but that concentrations of acetate, ketone bodies, cytosine, methylmalonate, and phenylacetylglycine were all higher. Another study identified pseudouridine and 2-oxoglutarate as 2 biomarkers of HF (7) . In the present study, we recruited more HF patients and examined the clinical applicability and significance of plasma metabolomic analysis in the diagnosis and prognosis of HF. We also sought to determine whether metabolomic analysis provides sensitive evaluation of HF at different stages and in disease regression after therapeutic interventions. analysis of variance, and chi-square test, when appropriate. Metabolomics analysis was performed using several software programs. Data import and pre-processing steps for targeted MS data were done using TargetLynx (Waters Corp.). The integrated MetIDQ software (Biocrates, Innsbruck, Austria) was applied to streamline data analysis by automated calculation of metabolite concentrations. To maximize identification of differences in metabolic profiles between groups, the orthogonal-projectionto-latent-structure-discriminant-analysis (OPLS-DA) model was applied using the SIMCA-P software Follow-up data were collected as scheduled or at the last available visit. Cox proportional hazard models were used to determine independent predictors of the first defined events (death or HF-related re-hospitalization) after controlling for covariates.
METHODS
Hazard ratios and 95% confidence intervals were also calculated. All statistical analyses were 2-sided and performed using SPSS software (version 15.0, SPSS, Chicago, Illinois). A p value of <0.05 was considered significant.
Detailed methods are provided in the Online
Appendix.
RESULTS
A total of 515 participants included 114 normal control subjects and 401 patients. The discovery phase included 234 participants, including 51 normal control subjects and 183 HF patients at stages A (n ¼ 43), B (n ¼ 67), and C (n ¼ 73) (Online Figure 1) . Baseline characteristics and laboratory data are shown in Table 1 . A significant trend of changes was noted in most of the variables for the normal control subjects to patients at HF stages A, B, and C. Compared with the normal control subjects, stage C patients had remarkably higher BNP levels and a wider QRS complex, but they also had lower levels of total cholesterol, low-and high-density lipoprotein cholesterol, sodium, hemoglobin, albumin, and in the estimated glomerular filtration rate. Although there were no significant differences in age among the patient groups, HF patients were older than the normal control subjects. In addition, the percent of men was higher in the patient groups. Coronary artery disease was the major HF etiology for study patients. The validation phase study included 63 normal control subjects and 218 stage C HF patients; the related demographic characteristic data are shown in Online Table 1 .
Initially, for the untargeted metabolomics analysis, 119 plasma samples, from 51 normal control subjects and 68 stage C HF patients from the 234 discovery phase participants, were examined (Online Figure 1 ).
In the metabolomic profiling, 897 positive-mode features were identified and applied for SIMCA-P analysis. The OPLS-DA score plot and loading plot showed remarkable separation between the control subjects and stage C HF patients (Online Figure 2) . The results of untargeted analysis revealed amino acids and phospholipids to be important discriminators between the normal control subjects and stage C HF patients. Therefore, stable isotope dilution-multiple reaction monitoring MS was performed in all 234 participants to quantify amino acids, biogenic amines, acylcarnitines, and phospholipids in both the discovery phase and validation groups.
To test whether metabolites could discriminate patients from control subjects, plasma from 51 normal control subjects and from 73 stage C HF patients in the discovery phase study were subject to targeted metabolite analysis, and datasets were analyzed by the OPLS-DA model. The OPLS-DA score plots demonstrated considerable separation between the normal control subjects and the stage C HF patients in the first principal component ( Figure 1A ; x-axis, called t [1] ), which probably reflected the HF-related pathological variations between the subjects. The metabolites responsible for the discrimination between these 2 groups (those with VIP >1.5) are listed in Table 2 and Online   Table 2 . This model (i.e., the "training set") was then used to estimate HF status in the following analyses.
The calculated value of this model is called tPS [1] . Figure 1B is the score plot of data corresponding to the age-matched control subjects (n ¼ 51) and stage C HF patients (n ¼ 50) in the discovery phase study, whose demographic characteristic data are shown in Online Table 3 . The distribution of the data in the score plots was similar to that shown in Figure 1A , suggesting that discrimination of the 2 groups was independent of age. On the basis of this training set, patients at stage A (n ¼ 43) and stage B (n ¼ 67) were calculated by tPS [1] (Figures 1C and 1D, respectively) . To discriminate between the patients at stage C HF and normal control subjects (diagnostic value), the receiver-operating characteristic curves were plotted for both BNP and t [1] (by taking all metabolites into the principal component analysis) ( Figure 1E ). The areas under the curves (AUCs) were 0.99 and 1.0, respectively. Notably, there were 4 important metabolites that significantly contributed to the diagnostic value for HF, namely, histidine, phenylalanine, spermidine, and phosphatidylcholine C34:4 (once known as "lecithin") ( Table 3 ). These 4 metabolites gave rise to an AUC of 0.99, which was better than that of each metabolite alone ( Figure 1E ). On the basis of the training set composed of these 4 metabolites, the score plot (tPS [2] ) distribution of the normal control subjects and the stage C HF patients are shown in Figure 1F . The odds ratio of the BNP and tPS [2] levels for identifying stage C HF (vs. normal control subjects) are presented in Table 3 . The diagnostic value of tPS [2] was independent of diabetes mellitus and other comorbidities. The targeted quantitative analysis of the validation set revealed similar diagnostic levels for the 4-metabolite panel as observed in the discovery samples ( Table 3 , Online Table 4 ). Values are mean AE SD or n (%). *Chronic kidney disease ¼ eGFR <60 ml/min/1.73 m 2 .
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; BNP ¼ B-type natriuretic peptide; COPD ¼ chronic obstructive pulmonary disease; eGFR ¼ estimated glomerular filtration rate; HDL-C ¼ high-density lipoprotein cholesterol; LDL-C ¼ low-density lipoprotein cholesterol; LVEF ¼ left ventricular ejection fraction; OHA ¼ oral hypoglycemic agents.
Cheng et al. The OPLS-DA score plots of patients at stages A and B, respectively. The ellipse shown in the model represents the Hotelling T-square test with 95% confidence. (E) The ROC curves for the diagnosis of HF by B-type natriuretic peptide (BNP), tPS [1] , and tPS [2] . (F) The OPLS-DA score plots represent the tPS [2] values calculated by combining 4 important metabolites. OPLS-DA ¼ orthogonal-projection-to-latent-structurediscriminant-analysis; ROC ¼ receiver-operating characteristic.
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VIP ¼ variable importance in the projection. The metabolites that changed at different stages are shown in Table 2 and Online Table 2 components (dimethylarginine/arginine ratio, spermidine, butyrylcarnitine, and total essential amino acid amount) gave rise to an optimal prognostic value that was remarkably better than BNP. The tPS [3] was calculated from these 4 metabolite components and the AUCs of receiver-operating characteristics curves for tPS [3] , tPS [1] , and BNP levels were 85%, 78%, and 74%, respectively ( Figure 2A) . Table 4 and Online Table 5 show the Cox univariable and multivariable analyses for these parameters on the prognosis. The prognostic value of tPS [3] was still highly significant even after adjusting for BNP levels, age, left ventricular ejection fraction, diabetes mellitus, chronic kidney disease, and hypertension. The validation study reconfirmed these findings ( Table 4 , Online Table 5 , Figure 2D ).
The mean of tPS [3] (2.9, range 0.04 to 5.63) was set as the cutoff value for the prognostic prediction. In Figure 2B , the Kaplan-Meier curves revealed that a tPS [3] of $2.9 at pre-discharge was associated with a higher composite of HF-related re-hospitalization and all-cause death (log rank ¼ 17.5; p < 0.0001 ). In comparison, the Kaplan-Meier curves of patients categorized according to BNP (cutoff value set at 350 pg/ml) (8) are shown in Figure 2C (log rank ¼ 9.9; p ¼ 0.002). The targeted quantitative analysis for the 4 metabolite components of the validation phase set revealed better prognostic levels than BNP than that observed in the discovery samples ( Figures 2D   to 2F ).
The correlation between tPS [2] and BNP levels was modest (r ¼ 0.53; p < 0.001) ( Figure 3A) . To verify the diagnostic value of tPS [2] , metabolomics analysis, together with BNP measurement, was also performed in 32 patients (22 men and 10 women; age 54 AE 11 years) who were recruited earlier than this study's enrollment period. These patients, named the "recovery" group, were initially hospitalized due to acute or decompensated chronic HF, but then they improved to New York Heart Association functional class I and survived for >1 year. Plasma was analyzed before discharge and again at 6 and 12 months postdischarge. The serial changes in tPS [2] and BNP values are shown in Figure 3B . The tPS [2] values for the 32 patients at pre-discharge stage were significantly higher than those of the normal control subjects (p < 0.001). Compared with pre-discharge levels,
both the values of tPS [2] and BNP remarkably decreased at 6 months and remained steady at 12 months after discharge (p < 0.001).
DISCUSSION
In the present study, we demonstrated that metab- (Top) The proposed scheme indicates that the decrease in cardiac output leads to disturbances of the metabolic pathways and the appearance of specific metabolites in the circulation of heart failure (HF) patients. These metabolites probably serve as biomarkers for HF. (Bottom) Disturbances occur in the following metabolic pathways:
(a) urea cycle, (b) biopterin cycle, (c) MTA/methionine cycle, (d) ornithine-proline-glutamate, (e) polyamine synthesis, (f) methylation (phosphatidylcholine), and (g) transsulfuration (taurine) in HF patients. Metabolites marked in salmon, blue, black, and gray indicate metabolites, the abundance of which significantly increased, significantly decreased, remained unchanged, and were not measured, respectively. a-KG ¼ alpha-ketoglutarate; BH 4 ¼ tetrahydrobiopterin; GAA ¼ guanidinoacetate;
Cheng et al. The ranges of t [1] and tPS [2] are from -2.64 to 2.5 and from -2.5 to 2.65, respectively. The ranges of tPS [3] s are from 0.04 to 5.6 and from 1.2 to 6.3 for the discovery phase and validation studies, respectively (on the basis of regression models). Tables 1 and 3 . [2] , and tPS [3] in the discovery phase study; and BNP and tPS [3] in the validation studies. (B, C, E, and F) The Kaplan-Meier curves of tPS [3] and BNP for predicting a composite event of all-cause death and HF-related re-hospitalization in the discovery phase and the validation studies. Abbreviations as in Figure 1 . Mitochondrial dysfunction and a shift from fatty acid to glucose utilization for energy production are the main metabolic changes seen in the failing heart. Histidine, which is capable of being converted to glutamate, enters the glutamate-ornithine-proline pathway or Krebs cycle as alpha-ketoglutarate, which supplies ornithine and energy for cardiac tissues.
Glucose can be converted to phosphoribosyl pyrophosphate, which is essential to histidine biosynthesis. Over-consumption of glucose as an energy source may impair the cellular ability to replenish histidine deficiency, which is probably caused by inadequate intake. Uncoupling of nitric oxide synthase may involve the pathogenesis of HF (10).
Induction of nitric oxide synthase-2 and concurrent tetrahydrobiopterin depletion in the myocardium contribute to HF in animal models and human subjects (10, 11) . Consistent with such notions, accumulation of phenylalanine and tyrosine in HF patients during progression from stage A to C HF are indicative of tetrahydrobiopterin depletion. This occurs in parallel with a significant decrease in arginine levels, which may disturb nitric oxide (NO) production and lead to cardiac dysfunction (12) . In contrast, the increased phenylalanine and tyrosine levels may also be associated with the accumulation of aromatic amino acids caused by increased muscular protein breakdown and impaired liver function.
Our study showed the stage-specific elevation of plasma polyamine metabolites, namely, spermidine and spermine. The polyamine and NO pathways are inter-regulated in several experimental models.
NO inhibits ornithine decarboxylase and polyamines production (13, 14) . Ornithine, the upstream precursor to polyamines formation, can be produced from Fischer ratio, which is the molar ratio of plasma branched chain amino acids levels to aromatic amino acids levels (22) .
Although some of these changes were also noted in our patients (Online Table 2 ), the main metabolic profile discovered in our study is distinct. Metabolic signatures are different between HF and non-HF cachexia. Cachexia related to chronic lung disease and cancer, for example, has been associated with increases in very low-and low-density lipoproteins (23), glutamine, aspartate, arginine, and asparagine, as well as decreases in aminoadipate, beta-aminoisobutyrate, and 1-methylhistidine (24).
Comparison of these reports and our findings suggest that the metabolic profiles described in our study are specific to HF. However, the specificity of our profiles for both diagnostic and prognostic values needs to be assessed in patients with non-HF diseases or dyspnea. In contrast, the same AUCs of BNP and tPS [2] suggest that metabolomics is highly valuable for evaluating HF-related metabolic disturbances. It 
